Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
.jpg)
UBS added that its strategists are positively surprised by the scope and tone of the Plenum document.
The investment bank adds that company's September-quarter earnings came in line with consensus estimates.
Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
The declines also tracked the Indian rupee, which fell to a record low as central bank measures to tighten capital outflows and curb gold imports were seen as unlikely to prop up the currency and could even spark further selling if they spook foreign investors.
Hindustan Unilever shares were up 3.7 per cent at 9.24 am after earlier hitting an all-time high of Rs 632.
Wage hikes and rupee depreciation may affect the business.
FIIs have been strong buyers of shares since last year until a recent streak of selling.
Acquisition to boost its generics business in developed markets.
DLF, which builds homes, offices and shopping malls, has lost about 61 per cent of its value since listing on the stock exchange in 2007, underperforming the wider market.
The company stock ended up 4.49 per cent.
The deal underscores a growing trend of consolidation in Asia's wealth management industry.
Would-be investors such as KKR, the Blackstone Group and Macquarie Group are looking at buying into completed projects.
Authorities claimed that a share sale by the company to its overseas parent in 2009 was undervalued by about Rs 15,200 crore.
The planned fund could help New Delhi raise between $1 billion and $2 billion.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
The buyer received poor investor response to the pricing of the share sale.
Wipro and HCL Technologies among its top picks.
Says the TRC proposal was clumsily worded.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances